Daiichi Sankyo has been granted a patent for a novel peptide that selectively binds to active proteases, specifically human MMP-9, while avoiding pro-proteases. The invention includes a conjugate featuring a SPINK2 mutant peptide with a defined amino acid sequence. GlobalData’s report on Daiichi Sankyo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Daiichi Sankyo, Cancer treatment biomarkers was a key innovation area identified from patents. Daiichi Sankyo's grant share as of June 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Novel peptide targeting active mmp-9 protease
The patent US12043658B2 describes a novel conjugate that includes a mutant peptide derived from SPINK2, which specifically binds to the active form of human matrix metalloproteinase-9 (MMP-9) while showing no affinity for its pro form. The claims detail that the SPINK2 mutant peptide can inhibit the protease activity of active MMP-9, with specificity to the human variant. The peptide may also be modified with additional amino acid residues at either the N-terminal or C-terminal ends, and it can incorporate structural features such as disulfide bonds, loop structures, a-helices, and ß-sheets. The conjugate can take various forms, including peptides or those that incorporate an immunoglobulin Fc region.
Additionally, the conjugate may be linked to various moieties, including drugs or labeling molecules, which can serve multiple purposes such as therapeutic applications or diagnostic imaging. The patent outlines methods for producing the SPINK2 mutant peptide through cell culture techniques and recovering it via affinity purification. Furthermore, it describes the synthesis of the conjugate through chemical methods or in vitro translation. This patent presents significant potential for applications in therapeutic and diagnostic fields, particularly in targeting MMP-9-related conditions.
To know more about GlobalData’s detailed insights on Daiichi Sankyo, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
